EFPIA Newsletter 19 January 2023

News     18 January 2023 Borders should no longer be barriers: The EU-X-CT Multi-stakeholder Initiative EFGCP and EFPIA launch initiative to enable cross-border access to clinical trials for all patients in Europe Read more →

The Power of Innovation Almost all cases of cervical cancer are caused by an infection from human papillomavirus (HPV). Since 2006, several vaccines against HPV have become available in the EU27, providing the opportunity to prevent more than 27,000 cervical cancer cases and 12,000 deaths, each year. Find out more.

Events     22 JAN 2023   enter the EURORDIS PHOTO AWARD 2023 Photo Award Celebrating inspiring individuals, organisations and companies who make a real difference in the rare disease community... Learn more →       24 JAN 2023   Launch event of the RETHINKING Alzheimer's disease White Paper Virtual event Registrations are now open. Learn more →

	25 JAN 2023			RETHINKING THE FUTURE OF CANCER CARE Virtual event Organised in partnership with the FT Live Learn more →

	31 JAN 2023			Even spaceships need a launchpad Virtual event Bring the regulatory framework for innovative medicines into the future Learn more →

What we are reading Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe 16 January 2023  (Financial Times) Read more → Solving the issue of medicine shortages in the EU 18 January 2023  (Euractiv) Read more →

About the EFPIA newsletter The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55 Communications@efpia.eu ▶ in

EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe